Q-omics provides the consensus-scored CT69 profile across patient tissues and cancer cell-line models. CT69 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CT69 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, CT69 RNA expression shows 12,955 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where CT69 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT69 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT69 survival associations across molecular data types. CT69 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT69 RNA expression–survival associations across cancer types. High CT69 expression shows unfavorable associations in UVM, COAD, LGG and BLCA, but favorable associations in KIRP and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CT69 RNA expression.
This table summarizes CT69 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CT69. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT69 shows lower tumor expression in KICH, KIRC, KIRP and PRAD and higher tumor expression in HNSC and LUSC. The KICH box plot shows higher CT69 RNA expression in normal versus tumor tissue (log2 FC = −0.653, t-test p < 0.001).
This table shows molecular features associated with CT69 in patient tissues and cancer cell lines. In patient samples, CT69 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
